/PRNewswire/ DelveInsight s Influenza A Market Insights report includes a comprehensive understanding of current treatment practices, influenza A emerging.
The influenza A market is expected to surge in the coming years as the emerging therapies which are under development will provide efficient therapeutic approaches with novel mechanisms of action
The seasonal influenza market size is anticipated to increase in the coming years owing to the launch of the emerging therapies and vaccines. The current pipeline of seasonal influenza consists
Share this article
Share this article
SAN DIEGO, March 9, 2021 /PRNewswire/ Viriom Inc., a San Diego CA-based biotech and Chromis, a joint venture of the ChemRar Group and the Russian Direct Investment Fund (RDIF) reported a summary of the multicenter, open-labeled, efficacy and safety study of Avifavir (favipiravir) in patients with COVID-19 at the Conference on Retroviruses and Opportunistic Infections CROI2021.
Background:
Favipiravir as well as remdesivir are currently the leading directly acting antiviral drugs against COVID-19 globally. Avifavir received emergency use authorization from Russia s Ministry of Health in May 2020 based on an interim report of an open label comparative Phase 2-3 clinical study in hospitalized medium severe and severely ill patients and became the world s first favipiravir-based drug approved for the treatment of COVID-19. It obtained full market authorization in November 2020 and was included in the Russian standard of care as a first li